NCT07127146

Opioidergic and Noradrenergic Systems in Central Parkisonian Pain

Role of Opioidergic and Noradrenergic Systems in Central Parkisonian Pain

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to evaluate the differences in functional physiopathology of the opioid and noradrenergic systems between Parkinson's patients with central pain and Parkinson's patients without central pain. Using PET-MRI data, investigators aim to observe opioids receptors availability using \[11C\]Carfentanil (µ opioid receptor agonist) and altered α2-AR density with \[11C\]Yohimbine (adrenergic α2 receptor antagonist).

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
OTHER	PET-MRI exam with administration of [11C]Carfentanil	Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Carfentanil and will last for 51 minutes in a resting state. The dose will be 250 MBq/kg +-10 %.
OTHER	PET-MRI exam with administration of [11C]Yohimbine	Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Yohimbine and will last for 70 minutes in a resting state. The dose will be 370 MBq/kg +- 10 %.

Timeline

• Start date: 2025-10-01
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2025-08-17
• Last updated: 2025-08-17

Locations

3 sites across 1 country: France